The GLP-1 Math Employers Can’t Afford to Ignore

Key Takeaway: GLP-1s can deliver meaningful value for the right members, but coverage alone is not a strategy. Employers need clear eligibility criteria, careful dose titration, early member education, lifestyle support and medication visibility to make a long-term investment more likely to hold.

Early in my career, I worked in a pharmacy environment where there was no margin for error.

Puerto Rico had high rates of chronic disease, constrained resources, and patients managing multiple conditions across multiple prescribers. You learned quickly that a prescription was never just a prescription. It was a decision. And decisions made without the full picture had consequences that showed up later: in a complication, a hospitalization, a therapy that stopped working because something else got in the way.

That's the lens I bring to the GLP-1 conversation. Because employers aren't just deciding whether to cover a drug. They're deciding whether to make a long-term clinical investment inside a workforce where turnover may prevent employers from ever seeing the long-term return.

That's the part of the GLP-1 debate that still isn't being talked about enough. The missing piece isn't only clinical. It's mathematical.

The GLP-1 ROI Math Employers Can't Ignore

GLP-1s for weight management are a long-term investment. The reduction in cardiovascular risk. Improvements in chronic conditions like diabetes, hypertension, and sleep apnea. Fewer hospitalizations. Lower reliance on other medications. The downstream medical savings tied to those outcomes rarely appear in the first few months of treatment. In many cases, they take years to fully materialize.

Now place that timeline next to another reality: according to the Bureau of Labor Statistics, the median tenure of a private-sector employee in the United States is 3.5 years — the lowest it's been in more than two decades. Among workers aged 25 to 34, the group most likely to be entering treatment for weight management, median tenure is 2.7 years.

That doesn't mean employers should avoid GLP-1 coverage for weight loss. It means they need to stop treating coverage alone as the strategy. Because the member who finally sees results in year two may be on a competitor's plan by then.

GLP-1s Can Deliver Value — For the Right Members

I'm not arguing against GLP-1 coverage.

For members who stay on therapy and maintain strong adherence, these drugs can deliver meaningful improvements in cardiometabolic health. For members carrying the greatest clinical risk — obesity with documented comorbidities, cardiovascular complications, uncontrolled diabetes — the case for investment can be compelling even accounting for turnover.

But most plans aren't built to get there.

What exists in many plans today isn't a strategy. It's a formulary line. A prior authorization. A prescription written by a telehealth provider or a primary care physician who had fifteen minutes. A member who starts too high, feels sick in the first week, and stops before the drug ever had a chance to work.

Not because the drug failed. Because no one was watching.

The plan paid for that. Got nothing back.

The clinical definition of obesity is a BMI above 30. Severe obesity — where disease burden is higher and the potential value of treatment may appear sooner — begins at 40. When employers treat every GLP-1 candidate the same, they fund therapy for members whose near-term clinical risk is lower, whose adherence is uncertain, and whose expected savings may not materialize before they leave the plan.

For members with type 2 diabetes, the math is different. GLP-1s are the standard of care for many diabetic patients, particularly those with obesity and cardiovascular risk. Restricting that access simply to control cost creates more risk than strategy.

But not every member belongs in the same clinical lane. The non-obese diabetic. The pre-diabetic. The person for whom an SGLT-2 inhibitor is the better fit. Those are the conversations a responsible pharmacy strategy demands. And many plans aren't having them.

What a Responsible Employer GLP-1 Program Requires

Before expanding GLP-1 coverage for weight loss, employers should be able to answer four questions.

• Who qualifies based on clinical risk? Eligibility should begin with members most likely to benefit within a realistic timeframe — beyond BMI alone, considering cardiometabolic risk, comorbidities, diabetes status, and the member's full clinical picture. The greater the clinical risk, the stronger the case for investment, even in a workforce where turnover is unavoidable.

• Is the starting dose being managed correctly? GLP-1 therapy should begin carefully — start low, go slow. Incorrect titration is one of the most avoidable causes of early discontinuation. A prior authorization that approves therapy but doesn't enforce appropriate dosing has only done half the job.

• Does the member know what to expect? The first eight weeks matter. Side effects can be expected and often manageable, but a member who isn't prepared may interpret them as failure. By week three, they may stop. That's not a drug problem. It's an education problem.

• Is there a plan for the whole person, not just the prescription? That means clinical monitoring — weight response, tolerability, dose progression — but it also means a lifestyle program alongside the medication. Nutritional guidance, behavioral coaching, regular check-ins. The evidence is clear that much of the weight loss achieved on a GLP-1 can reverse when therapy stops. The medication may do the heavy lifting in the short term. But if employers want the investment to last, lifestyle support has to happen in parallel: nutrition, behavioral coaching, regular check-ins, and habits that can survive beyond the prescription.

The Safety Risk of Direct-to-Consumer GLP-1 Access

The next phase of the GLP-1 conversation may be even more complicated.

Employers are increasingly exploring reimbursement arrangements for weight loss coverage — removing GLP-1s for obesity from the standard formulary and offering members a fixed monthly contribution toward direct-to-consumer purchases instead. The economics are hard to ignore: plans may be paying hundreds of dollars more per member per month through the benefit, while some direct-to-consumer manufacturer programs now advertise cash-pay options in the low hundreds.

But there's a clinical risk hiding inside those economics.

When a member receives a GLP-1 outside the pharmacy benefit, that prescription often disappears from view. It doesn't adjudicate through the plan. It may not be screened against the rest of the member's medications — the diabetes therapy, the cardiovascular drugs, the acid reducers that can interact in ways that matter clinically.

From where I sit, from the perspective of a team that reviews prescriptions before they reach members, that catches the combinations that shouldn't have moved forward, that's not just a cost issue. It's a safety issue. Any model that routes GLP-1s outside the pharmacy benefit needs to answer one question: how does that prescription get back into view?

The Honest GLP-1 Answer for Employers

The medical cost improvements from GLP-1s are real, but the full net savings story is still developing. And workforce tenure makes the timeline even harder to close.

That doesn't make GLP-1s a bad investment. It makes them an investment that has to be managed, and one that rewards employers who approach it with precision.

The employers who will make the investment hold will be the ones who defined eligibility clearly, enforced clinical structure at the start, prepared members for what to expect, built lifestyle support into the program, kept a close eye on adherence, and kept every prescription visible regardless of where it was filled.

If you're evaluating GLP-1 coverage for your population, or reconsidering a program that isn't performing the way you hoped, these are the conversations worth having now. Talk to your benefits consultant. Talk to your PBM. Ask whether your current strategy can answer the four questions in this article. If it can't, that's where to start.

GLP-1s may become one of the most important health investments employers make this decade. The employers who realize that value won't be the ones who covered the most. They'll be the ones who covered the right members, in the right way, with the right people watching.

FAQs

How should employers decide who qualifies for GLP-1 coverage?

Eligibility should consider the member’s full clinical risk, including obesity-related comorbidities, cardiometabolic risk and diabetes status, rather than relying on BMI alone.

Why does GLP-1 dose titration matter for employers and members?

Starting too high or advancing doses too quickly can increase side effects and early discontinuation. Careful titration helps members stay on therapy long enough to realize potential benefit.

What support should an employer GLP-1 program include?

A strong program should include member education, clinical monitoring, lifestyle support and regular follow-up to help members manage side effects, sustain adherence and build healthier habits alongside medication.

What are the risks of GLP-1s purchased outside the pharmacy benefit?

When a GLP-1 is filled outside the benefit, it may not be visible alongside the member’s other medications. Plans should understand how those prescriptions will remain part of a complete clinical picture.